TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cocrystal Pharma ( (COCP) ) just unveiled an announcement.
On December 1, 2025, Cocrystal Pharma announced that its CFO and Co-CEO, James Martin, will present a company overview and clinical progress update at the Noble Capital Markets 21st Emerging Growth Equity Conference on December 3, 2025. This presentation could enhance the company’s visibility and provide stakeholders with insights into its strategic direction and progress in antiviral drug development.
The most recent analyst rating on (COCP) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Cocrystal Pharma stock, see the COCP Stock Forecast page.
Spark’s Take on COCP Stock
According to Spark, TipRanks’ AI Analyst, COCP is a Underperform.
Cocrystal Pharma faces significant financial challenges, with no revenue and ongoing operational losses severely affecting its stock score. The technical analysis indicates potential downward pressure, while the negative valuation metrics are concerning. However, recent corporate events provide some positive aspects, suggesting future growth potential. Overall, the company’s stock score reflects these mixed factors, indicating substantial risk with some long-term opportunities.
To see Spark’s full report on COCP stock, click here.
More about Cocrystal Pharma
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on developing innovative antiviral treatments for diseases such as influenza, viral gastroenteritis, COVID, and hepatitis. The company utilizes unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.
Average Trading Volume: 1,551,274
Technical Sentiment Signal: Strong Sell
Current Market Cap: $14.61M
See more insights into COCP stock on TipRanks’ Stock Analysis page.